Related Experiment Video

Updated: Mar 29, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.4K

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Shundong Cang1, Chaitanya Iragavarapu2, John Savooji2

  • 1Department of Oncology, The Henan Province People's Hospital, Zhengzhou, China.

Journal of Hematology & Oncology
|November 22, 2015
PubMed

Insights

New treatments for chronic lymphoid leukemia (CLL) are emerging, including B-cell lymphoma-2 (BCL-2) inhibitors like venetoclax. This review covers the latest clinical developments of venetoclax and other novel agents targeting BCL-2 proteins for CLL treatment.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic lymphoid leukemia (CLL) treatment landscape is expanding with novel targeted agents.
  • B-cell lymphoma-2 (BCL-2) is a key regulator of apoptosis and a promising therapeutic target in CLL.
  • Small molecule inhibitors targeting BCL-2 are under active clinical investigation.

Purpose of the Study:

  • To review the latest clinical developments of ABT-199 (venetoclax) and other novel agents targeting BCL-2 proteins.
  • To provide an overview of emerging treatment options for chronic lymphoid leukemia.

Main Methods:

  • Literature review of clinical studies and trials.
  • Summary of data on novel agents targeting BCL-2 proteins.
  • Focus on ABT-199/venetoclax clinical development.

Main Results:

  • ABT-199 (venetoclax) has received FDA breakthrough designation for relapsed/refractory CLL with 17p deletion.
  • Multiple novel agents targeting BCL-2 proteins are in active clinical development for CLL.
  • The advent of these agents signifies a paradigm shift in CLL therapeutic options.

Conclusions:

  • Venetoclax and other BCL-2 inhibitors represent a significant advancement in CLL therapy.
  • Targeting BCL-2 offers a promising strategy for managing chronic lymphoid leukemia.
  • Further clinical development is ongoing for these novel agents in CLL treatment.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K